RA
FDMT icon

Royce & Associates’s 4D Molecular Therapeutics FDMT Stock Holding History

Royce & Associates’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,769
Closed -$380K – 892
2023
Q4 		$380K Buy
+18,769
New +$247K ﹤0.01% 807
2022
Q1 		– Sell
-9,300
Closed -$204K – 981
2021
Q4 		$204K Buy
+9,300
New +$228K ﹤0.01% 945

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates's FDMT Position: Q1 2024 in Review

Royce & Associates sold out of 4D Molecular Therapeutics (FDMT) in Q1 2024, closing a stake of 18,769 shares — an estimated $380K sold.

Royce & Associates first reported a position in FDMT in Q4 2021 and held it in 2 quarters. The position peaked at $380K in Q4 2023. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

  • Royce & Associates reported no remaining 4D Molecular Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Royce & Associates sold 18,769 4D Molecular Therapeutics shares in Q1 2024, an estimated $380K.
  • Royce & Associates first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 2 quarters.
  • Royce & Associates's 4D Molecular Therapeutics position peaked at $380K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Royce & Associates's 13F filing for Q1 2024, filed 13 May 2024.